PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.73%
R&D reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive implications.
522.30%
G&A change of 522.30% versus flat Healthcare overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
3069944.64%
Other expenses change of 3069944.64% versus flat Healthcare costs. Walter Schloss would verify efficiency.
230.56%
Operating expenses growth exceeding 1.5x Healthcare median of 2.84%. Jim Chanos would check for waste.
230.56%
Total costs growth exceeding 1.5x Healthcare median of 2.91%. Jim Chanos would check for waste.
243.75%
Interest expense change of 243.75% versus flat Healthcare costs. Walter Schloss would verify control.
418.75%
D&A change of 418.75% versus flat Healthcare D&A. Walter Schloss would verify adequacy.
-202.01%
EBITDA decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-230.56%
Operating income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-494.03%
Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
-176.90%
Pre-tax income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-100.18%
Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
-176.90%
Net income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
89.62%
EPS change of 89.62% versus flat Healthcare. Walter Schloss would verify quality.
89.62%
Diluted EPS change of 89.62% versus flat Healthcare. Walter Schloss would verify quality.
2567.99%
Share count change of 2567.99% versus stable Healthcare. Walter Schloss would verify approach.
2567.99%
Diluted share change of 2567.99% versus stable Healthcare. Walter Schloss would verify approach.